
Martijn P W Intven

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4822162/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Frailty and health related quality of life three months after non-metastatic colorectal cancer diagnosis in older patients: A multi-centre prospective observational study. Journal of Geriatric Oncology, 2022, 13, 74-81.	1.0	4
2	Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. Hpb, 2022, 24, 535-546.	0.3	9
3	Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands. Annals of Surgery, 2022, 275, 769-775.	4.2	32
4	Impact of Dose-Escalated Chemoradiation on Quality of Life in Patients With Locally Advanced Rectal Cancer: 2-Year Follow-Up of the Randomized RECTAL-BOOST Trial. International Journal of Radiation Oncology Biology Physics, 2022, 112, 694-703.	0.8	5
5	Intrafraction pancreatic tumor motion patterns during ungated magnetic resonance guided radiotherapy with an abdominal corset. Physics and Imaging in Radiation Oncology, 2022, 21, 1-5.	2.9	11
6	Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac. Acta OncolÃ ³ gica, 2022, 61, 111-115.	1.8	26
7	Most patients reported positively or neutrally of having served as controls in the trials within cohorts design. Journal of Clinical Epidemiology, 2022, 148, 39-47.	5.0	6
8	Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 5988-5999.	1.5	11
9	ASO Visual Abstract: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Annals of Surgical Oncology, 2022, , .	1.5	Ο
10	Impact of magnetic resonance-guided versus conventional radiotherapy workflows on organ at risk doses in stereotactic body radiotherapy for lymph node oligometastases. Physics and Imaging in Radiation Oncology, 2022, 23, 66-73.	2.9	5
11	Dosimetric feasibility of hypofractionation for SBRT treatment of lymph node oligometastases on the 1.5T MR-linac. Radiotherapy and Oncology, 2021, 154, 243-248.	0.6	9
12	Oncology patients were found to understand and accept the Trials within Cohorts design. Journal of Clinical Epidemiology, 2021, 130, 135-142.	5.0	7
13	Impact of a vacuum cushion on intrafraction motion during online adaptive MR-guided SBRT for pelvic and para-aortic lymph node oligometastases. Radiotherapy and Oncology, 2021, 154, 110-117.	0.6	11
14	A field strength independent MR radiomics model to predict pathological complete response in locally advanced rectal cancer. Radiologia Medica, 2021, 126, 421-429.	7.7	67
15	Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac: clinical implementation and initial experience. Radiotherapy and Oncology, 2021, 154, 172-178.	0.6	58
16	MR-Guided Radiotherapy for Rectal Cancer: Current Perspective on Organ Preservation. Frontiers in Oncology, 2021, 11, 619852.	2.8	27
17	Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Frontiers in Oncology, 2021, 11, 628155.	2.8	27
18	Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. International Journal of Radiation Oncology Biology Physics, 2021, 111, 867-875.	0.8	37

MARTIJN P W INTVEN

#	Article	IF	CITATIONS
19	Progression-free survival in patients with ⁶⁸ Ga-PSMA-PET-directed SBRT for lymph node oligometastases. Acta Oncológica, 2021, 60, 1342-1351.	1.8	9
20	Planning target volume margin assessment for online adaptive MR-guided dose-escalation in rectal cancer on a 1.5ÂT MR-Linac. Radiotherapy and Oncology, 2021, 162, 150-155.	0.6	18
21	Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?. Frontiers in Oncology, 2021, 11, 744161.	2.8	5
22	Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics. Radiotherapy and Oncology, 2020, 142, 246-252.	0.6	61
23	The trials within cohorts design facilitated efficient patient enrollment and generalizability in oncology setting. Journal of Clinical Epidemiology, 2020, 120, 33-39.	5.0	25
24	Patient-Reported Work Ability During the First Two Years After Rectal Cancer Diagnosis. Diseases of the Colon and Rectum, 2020, 63, 578-587.	1.3	12
25	The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Frontiers in Oncology, 2020, 10, 1328.	2.8	81
26	Efficacy of Dose-Escalated Chemoradiation on Complete Tumor Response in Patients with Locally Advanced Rectal Cancer (RECTAL-BOOST): A Phase 2 Randomized Controlled Trial. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1008-1018.	0.8	51
27	Target coverage and dose criteria based evaluation of the first clinical 1.5T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment. Radiotherapy and Oncology, 2020, 146, 118-125.	0.6	43
28	The effect of neoadjuvant short-course radiotherapy and delayed surgery versus chemoradiation on postoperative outcomes in locally advanced rectal cancer patients – A propensity score matched nationwide audit-based study. European Journal of Surgical Oncology, 2020, 46, 1605-1612.	1.0	4
29	Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results. Radiation Oncology, 2020, 15, 41.	2.7	3
30	Individual lymph nodes: "See it and Zap it― Clinical and Translational Radiation Oncology, 2019, 18, 46-53.	1.7	23
31	MRI-based tumor inter-fraction motion statistics for rectal cancer boost radiotherapy. Acta Oncológica, 2019, 58, 232-236.	1.8	14
32	Health-related quality of life in rectal cancer patients undergoing neoadjuvant chemoradiation with delayed surgery versus short-course radiotherapy with immediate surgery: a propensity score-matched cohort study. Acta Oncológica, 2019, 58, 407-416.	1.8	18
33	The effect of time interval from chemoradiation to surgery on postoperative complications in patients with rectal cancer. European Journal of Surgical Oncology, 2019, 45, 1584-1591.	1.0	3
34	Adaptive radiotherapy: The Elekta Unity MR-linac concept. Clinical and Translational Radiation Oncology, 2019, 18, 54-59.	1.7	330
35	Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT. Advances in Radiation Oncology, 2019, 4, 596-604.	1.2	11
36	Feasibility of stereotactic radiotherapy using a 1.5â€ [−] T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases. Radiotherapy and Oncology, 2019, 134, 50-54.	0.6	116

MARTIJN P W INTVEN

#	Article	IF	CITATIONS
37	Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. Hpb, 2018, 20, 297-304.	0.3	46
38	Effect of Neoadjuvant Therapy and Rectal Surgery on Health-related Quality of Life in Patients With Rectal Cancer During the First 2 Years After Diagnosis. Clinical Colorectal Cancer, 2018, 17, e499-e512.	2.3	58
39	Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer. European Journal of Surgical Oncology, 2018, 44, 1013-1017.	1.0	31
40	Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer. Radiotherapy and Oncology, 2018, 126, 437-442.	0.6	21
41	Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer. Hpb, 2018, 20, 204-215.	0.3	50
42	Does setup on rectal wall improve rectal cancer boost radiotherapy?. Radiation Oncology, 2018, 13, 61.	2.7	4
43	Utility Scores and Preferences for Surgical and Organ-Sparing Approaches for Treatment of Intermediate and High-Risk Rectal Cancer. Diseases of the Colon and Rectum, 2018, 61, 911-919.	1.3	12
44	Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients AgedÂ≥ 70 Years With Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2018, 17, 179-186.	2.3	6
45	The impact of postoperative complications on health-related quality of life in older patients with rectal cancer; a prospective cohort study. Journal of Geriatric Oncology, 2018, 9, 102-109.	1.0	41
46	Tumor volume regression during preoperative chemoradiotherapy for rectal cancer: a prospective observational study with weekly MRI. Acta Oncológica, 2018, 57, 723-727.	1.8	31
47	Long-term health-related quality of life after pancreatic resection for malignancy in patients with and without severe postoperative complications. Hpb, 2018, 20, 188-195.	0.3	38
48	Feasibility of magnetic resonance imaging-only rectum radiotherapy with a commercial synthetic computed tomography generation solution. Physics and Imaging in Radiation Oncology, 2018, 7, 58-64.	2.9	22
49	Imaging predictors of treatment outcomes in rectal cancer: An overview. Critical Reviews in Oncology/Hematology, 2018, 129, 153-162.	4.4	17
50	The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. European Journal of Radiology, 2018, 106, 128-136.	2.6	53
51	Dose evaluation of fast synthetic-CT generation using a generative adversarial network for general pelvis MR-only radiotherapy. Physics in Medicine and Biology, 2018, 63, 185001.	3.0	188
52	Abstract CT067: The Prospective Dutch ColoRectal Cancer Cohort (PLCRC): a prospective nationwide observational cohort study providing the infrastructure for registry based trials. , 2017, , .		0
53	Diffusion-weighted MRI for Early Prediction of Treatment Response on Preoperative Chemoradiotherapy for Patients With Locally Advanced Rectal Cancer. Annals of Surgery, 2016, 263, 522-528.	4.2	34
54	Evolution of motion uncertainty in rectal cancer: implications for adaptive radiotherapy. Physics in Medicine and Biology, 2016, 61, 1-11.	3.0	30

MARTIJN P W INTVEN

#	Article	IF	CITATIONS
55	OC-0365: The need for anatomical landmarks in adaptive rectal cancer boost radiotherapy. Radiotherapy and Oncology, 2016, 119, S169-S170.	0.6	0
56	Inter-observer agreement of MRI-based tumor delineation for preoperative radiotherapy boost in locally advanced rectal cancer. Radiotherapy and Oncology, 2016, 118, 399-407.	0.6	33
57	PD-0455: Combined T2w volumetry, DW-MRI and DCE-MRI for response assessment after chemoradiation in rectal cancer. Radiotherapy and Oncology, 2015, 115, S223.	0.6	1
58	RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial. Trials, 2015, 16, 58.	1.6	55
59	PO-0784: Rectal tumor volume shrinkage evaluated with MRI during preoperative chemoradiotherapy. Radiotherapy and Oncology, 2015, 115, S391-S392.	0.6	0
60	Combined T2w volumetry, DW-MRI and DCE-MRI for response assessment after neo-adjuvant chemoradiation in locally advanced rectal cancer. Acta Oncológica, 2015, 54, 1729-1736.	1.8	48
61	Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neoâ€adjuvant chemoradiation. Journal of Magnetic Resonance Imaging, 2015, 41, 1646-1653.	3.4	82
62	OC-0049: Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neo-adjuvant chemoradiation. Radiotherapy and Oncology, 2014, 111, S18.	0.6	1
63	Statistical Modeling of CTV Motion andÂDeformation for IMRT of Early-Stage RectalÂCancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 664-672.	0.8	15
64	Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: A systematic review and meta-analysis. Radiotherapy and Oncology, 2014, 113, 1-9.	0.6	124
65	Repeatability of diffusionâ€weighted imaging in rectal cancer. Journal of Magnetic Resonance Imaging, 2014, 40, 146-150.	3.4	25
66	OC-0574: MRI-based inter-fraction motion analysis for rectal cancer boost radiotherapy. Radiotherapy and Oncology, 2014, 111, S224-S225.	0.6	2
67	Diffusion-weighted MRI in locally advanced rectal cancer. Strahlentherapie Und Onkologie, 2013, 189, 117-122.	2.0	87
68	Kidney motion during free breathing and breath hold for MR-guided radiotherapy. Physics in Medicine and Biology, 2013, 58, 2235-2245.	3.0	27
69	PD-0412: Repeatability of diffusion weighted imaging in rectal cancer. Radiotherapy and Oncology, 2013, 106, S158-S159.	0.6	0
70	Target volume delineation variation in radiotherapy for early stage rectal cancer in the Netherlands. Radiotherapy and Oncology, 2012, 102, 14-21.	0.6	62
71	OC-0023 GATED MRI-LINAC (MRL) TREATMENT FOR KIDNEYS: INTER BREATH HOLD VARIATIONS. Radiotherapy and Oncology, 2012, 103, S8.	0.6	0
72	PD-0565 DIFFUSION-WEIGHTED MR IMAGING FOR PATIENT SELECTION FOR ORGAN-SPARING TREATMENT IN LOCALLY ADVANCED RECTAL CANCER. Radiotherapy and Oncology, 2012, 103, S226.	0.6	0

#	Article	IF	CITATIONS
73	446 poster REPRODUCIBILITY STUDY OF DIFFUSION-WEIGHTED IMAGING IN RECTAL CANCER Radiotherapy and Oncology, 2011, 99, S180.	0.6	ο